Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 16, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary Share ADR holdings for specific individuals following the reinvestment of dividends paid on July 12, 2007. The transaction price was $52.26 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding insider trading rules (Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b)).
Key Facts for Investors to Verify
- Dividend reinvestment occurred on July 12, 2007, at a price of $52.26 per ADR.
- Specific increases in holdings were recorded for Dr. JP Garnier (1,626.40 ADRs), Mr. D J Phelan (313.68 ADRs), and Mr. D M Stout (125.38 ADRs).
- The filing is a regulatory notification and does not contain operational or financial performance data.